 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Drug:
|
Atomoxetine
|
|
Clinical Trial ID:
|
NCT00216281
|
|
Mode of action:
|
NE/5HT transporter inhibitor
|
|
Phase:
|
POC Failed
|
|
Company:
|
University of Indiana
|
|
Note:
|
No effect on cognition or negative symptoms as add-on;
slight improvement of extra-pyramidal symptoms
|
Kelly DL, Buchanan RW, Boggs DL, McMahon RP, Dickinson D,
Nelson M, Gold JM, Ball MP, Feldman S, Liu F, Conley RR. A
randomized double-blind trial of atomoxetine for cognitive
impairments in 32 people with schizophrenia. J Clin
Psychiatry . 2009 Apr 1 ; 70(4):518-25. Abstract
Kratochvil CJ, Vaughan BS, Daughton JM, Mayfield-Jorgensen
ML, Burke WJ. Atomoxetine in the treatment of attention
deficit hyperactivity disorder. Expert Rev Neurother. 2004
Jul 1 ; 4(4):601-11. Abstract
|
|
|
|
|
Text Size 
See our most recent Schizophrenia Bulletin theme Webinar: